SEN 177

Product Description

SEN 177 is a potent glutaminyl cyclase (QPCT) inhibitor (IC₅₀ = 53 nM). SEN 177 reduces aggregation of mutant huntingtin (mHTT) through inhibition of QPCT and reduces Q80 aggregates in vitro. Inhibition of QPCT also reduces aggregate formation in in vivo models of Huntington's disease. SEN 177 potently inhibits QPCT-like protein (IC₅₀ = 13 nM) and disrupts binding of SIRP-α to CD47. The compound increases antibody-dependent cellular phagocytosis and cytotoxicity in cancer cell lines.

Solubility

Preparing Stock Solutions for SEN 177

The following data is based on the product molecular weight 338.39

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	14.78 mL	73.88 mL	147.76 mL
1 mM	2.96 mL	14.78 mL	29.55 mL
2 mM	1.48 mL	7.39 mL	14.78 mL
10 mM	0.30 mL	1.48 mL	2.96 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Logtenberg Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy. Nat.Med. 2019 PMID: 30833751
• Jimenez-Sanchez siRNA screen identifies QPCT as a druggable target for Huntington's disease. Nat.Chem.Biol. 2015 PMID: 25848931